Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CVRx Inc(CVRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CVRX
09/15/2026: CVRX (1-star) is currently NOT-A-BUY. Pass it for now.
CVRx Inc is a commercial-stage medical device company focused on treating heart failure through its proprietary Barostim neuromodulation technology. The company’s primary strength is its unique, first-in-class, FDA-approved device that provides an alternative to traditional pharmaceutical care. The investment story centers on the company’s ability to scale its reach through increased physician adoption and expanded insurance coverage. However, risks include heavy competition from large-cap device manufacturers, the reliance on a single product platform, and the challenge of establishing broad market penetration. CVRx may best suit growth investors interested in medical innovation, though it requires monitoring of commercial adoption rates and payer coverage updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a commercial-stage medical device provider with significant market penetration potential. |
| Momentum investor | Mixed fit | Momentum appeal is conditional on consistent growth signals and positive market adoption milestones. |
| Value investor | Weak fit | The company is in a growth-focused phase with limited profitability, making traditional value metrics less applicable. |
| Dividend investor | Weak fit | CVRx does not pay a dividend as it prioritizes reinvestment into market expansion. |
| Low-risk investor | Weak fit | The volatility associated with emerging medical technology companies makes it less suitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap medical device stocks often experience significant price swings based on commercial progress or study data. |
| Valuation risk | Medium / high | Valuations are highly sensitive to revenue growth forecasts and market adoption assumptions. |
| Competition risk (large cap device manufacturers) | High | Established players have superior resources to defend their market share against emerging therapies. |
| Business quality | Medium | The business relies on a single proprietary platform, creating both potential for high returns and concentration risk. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | Medium / high | The company must successfully navigate complex sales and reimbursement landscapes to achieve scale. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -27.61% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.92M USD | Price to earnings Ratio - | 1Y Target Price 4.58 |
Price to earnings Ratio - | 1Y Target Price 4.58 | ||
Volume (30-day avg) 1.4M shares | Beta 0.76 | 52 Weeks Range 2.20 - 11.30 | Updated Date 09/15/2026 |
52 Weeks Range 2.20 - 11.30 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Barostim System Sales | Sale of implantable pulse generators and associated leads for heart failure treatment. | Revenue is generated entirely through the adoption and sale of their specific heart failure device. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74.60M | Price to Sales(TTM) 1.31 |
Enterprise Value 74.60M | Price to Sales(TTM) 1.31 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 26.64M | Shares Floating 15.55M |
Shares Outstanding 26.64M | Shares Floating 15.55M | ||
Percent Insiders 15.2 | Percent Institutions 65.81 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About CVRx Inc
Exchange NASDAQ | Headquarters Minneapolis, MN, United States | ||
IPO Launch date 2021-06-30 | President, CEO & Director Mr. Kevin Hykes | ||
Sector Healthcare | Industry Medical Devices | Full time employees 223 | Website https://www.barostim.com |
Full time employees 223 | Website https://www.barostim.com | ||
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.